Pharmaceutical Executive February 27, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Arun Krishna, VP, Head of US Lung Cancer Franchise, AstraZeneca, talks about the FDA’s approval of TAGRISSO with the addition of chemotherapy in adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
PE: Recently, AstraZeneca announced the FDA approval for TAGRISSO with the addition of chemotherapy in adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). For our audience, can you briefly explain what this could mean for the future of lung cancer treatment?
Krishna: FLAURA2 is the study. It’s a follow up of FLAURA, where it was actually a TAGRISSO monotherapy, which is provided in...
Today's Sponsors
Today's Sponsor